The use of p38 inhibitors in AD transgenic mice was extensively studied [53,54,55,56,57], and, for example, a report using NJK14047 has shown interesting results including a reduction in brain Aβ accumulation, attenuated spatial learning deficit, and decreased neurotoxicity and cerebral neuroinflammatory markers [56]. The gene discussed is MAPK14; the disease is Alzheimer disease.